News

How multiple infections make malaria worse


 

Plasmodium sporozoite

Image by Ute Frevert

and Margaret Shear

New research suggests that infections with 2 types of malaria parasite lead to greater health risks because 1 species helps the other thrive.

Investigators sought to understand what happens when the 2 most common malaria parasites cause infection at the same time, as they are known to attack the body in different ways.

The team found the first parasite helps provide the second with more of the resources it needs to prosper.

“Immune responses are assumed to determine the outcome of interactions between parasite species, but our study clearly shows that resources can be more important,” said Sarah Reece, of the University of Edinburgh in Scotland.

“Our findings also challenge ideas that 1 species will outcompete the other, which explains why infections involving 2 parasite species can pose a greater health risk to patients.”

Dr Reece and her colleagues recounted these findings in Ecology Letters.

In humans, the malaria parasite Plasmodium falciparum infects red blood cells of all ages, while the Plasmodium vivax parasite attacks only young red blood cells.

The current study, conducted in mice with equivalent malaria parasites (P chabaudi and P yoelii), showed that the body’s response to the first infection produces more of the type of red blood cell the second parasite needs.

In response to the first infection, millions of red blood cells are destroyed. The body responds by replenishing these cells.

The fresh cells then become infected by the second type of parasite, making the infection worse.

The investigators said these results appear to explain why infections with both P falciparum and P vivax often have worse outcomes for patients than infections with a single malaria parasite.

Recommended Reading

Efficacy of malaria vaccine declines over time
MDedge Hematology and Oncology
Computer model shows how spleen filters blood
MDedge Hematology and Oncology
Agreements may constrain publication of trial results
MDedge Hematology and Oncology
Artemisinin resistance confined to Asia, study shows
MDedge Hematology and Oncology
Immunotherapy drugs linked to rheumatic diseases
MDedge Hematology and Oncology
P vivax evolving differently in different regions
MDedge Hematology and Oncology
HCPs may underestimate cancer risk from CT scans
MDedge Hematology and Oncology
FDA authorizes use of new Zika assay
MDedge Hematology and Oncology
Antiplatelet therapy could treat Alzheimer’s disease
MDedge Hematology and Oncology
Late sepsis death not explained by pre-existing conditions
MDedge Hematology and Oncology